OC
PTCT icon

Oppenheimer & Co’s PTC Therapeutics PTCT Stock Holding History

Oppenheimer & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,698
Closed -$346K – 1315
2019
Q2 		$346K Sell
7,698
-900
-10% -$35.5K 0.01% 951
2019
Q1 		$323K Sell
8,598
-3,500
-29% -$118K 0.01% 1008
2018
Q4 		$416K Sell
12,098
-2,500
-17% -$89.9K 0.01% 805
2018
Q3 		$686K Sell
14,598
-500
-3% -$20.7K 0.02% 735
2018
Q2 		$509K Sell
15,098
-1,900
-11% -$59.3K 0.01% 855
2018
Q1 		$460K Sell
16,998
-495
-3% -$12.5K 0.01% 884
2017
Q4 		$292K Buy
17,493
+2,400
+16% +$40.6K 0.01% 1067
2017
Q3 		$302K Sell
15,093
-27,500
-65% -$538K 0.01% 1033
2017
Q2 		$781K Buy
42,593
+18,273
+75% +$246K 0.02% 681
2017
Q1 		$239K Sell
24,320
-23,840
-50% -$289K 0.01% 1092
2016
Q4 		$525K Sell
48,160
-2,552
-5% -$26.8K 0.02% 792
2016
Q3 		$710K Sell
50,712
-36,744
-42% -$299K 0.02% 677
2016
Q2 		$613K Buy
87,456
+16,229
+23% +$119K 0.02% 716
2016
Q1 		$459K Buy
71,227
+12,636
+22% +$219K 0.01% 789
2015
Q4 		$1.9M Buy
58,591
+38,148
+187% +$1.12M 0.06% 363
2015
Q3 		$546K Buy
20,443
+3,136
+18% +$134K 0.02% 774
2015
Q2 		$833K Buy
17,307
+8,387
+94% +$489K 0.02% 686
2015
Q1 		$542K Buy
8,920
+4,320
+94% +$264K 0.01% 836
2014
Q4 		$238K Sell
4,600
-5,157
-53% -$227K 0.01% 1128
2014
Q3 		$429K Buy
+9,757
New +$305K 0.01% 912

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Oppenheimer & Co's PTCT Position: Q3 2019 in Review

Oppenheimer & Co sold out of PTC Therapeutics (PTCT) in Q3 2019, closing a stake of 7,698 shares — an estimated $346K sold.

Oppenheimer & Co first reported a position in PTCT in Q3 2014 and held it in 20 quarters. The position peaked at $1.9M in Q4 2015. 184 funds tracked by Wall St. Rank hold PTCT as of Q3 2019.

  • Oppenheimer & Co reported no remaining PTC Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 7,698 PTC Therapeutics shares in Q3 2019, an estimated $346K.
  • Oppenheimer & Co first reported a position in PTC Therapeutics in Q3 2014 and held it in 20 quarters.
  • Oppenheimer & Co's PTC Therapeutics position peaked at $1.9M in Q4 2015.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2019.

Based on Oppenheimer & Co's 13F filing for Q3 2019, filed 31 Oct 2019.